BrightPath Biotherapeutics Co., Ltd.
Research BrightPath Biotherapeutics Co., Ltd. (4594.T) on Bullrun: market cap JPY 5.97B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4594.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 5.97B
- Financial periodFY2026
- RevenueJPY 84.00K
- Revenue growth-92.6%
- Net income-JPY 1.30B
- Free cash flow-JPY 1.37B
- Gross margin64.3%
Valuation Snapshot
latest market cap is JPY 5.97B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 84.00K | -JPY 1.30B | -JPY 1.37B | 64.3% | -11.7 | JPY 2.16B | JPY 0 | JPY 2.37B |
| FY2025 | JPY 1.13M | -JPY 1.15B | -JPY 1.25B | 97.2% | -14.12 | JPY 810.47M | JPY 25.00M | JPY 924.99M |
| FY2024 | JPY 72.00K | -JPY 1.17B | -JPY 1.16B | 75.0% | -18.21 | JPY 1.06B | JPY 112.50M | JPY 978.99M |
| FY2023 | JPY 5.28M | -JPY 1.49B | -JPY 1.21B | 64.1% | -24.9 | JPY 1.53B | JPY 0 | JPY 1.57B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 5.97B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About BrightPath Biotherapeutics Co., Ltd.
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers. In addition, its product candidates in preclinical trials include BP1200 that targets CD73;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BrightPath Biotherapeutics Co., Ltd.'s market cap?
BrightPath Biotherapeutics Co., Ltd.'s market capitalization is JPY 5.97B.
What does BrightPath Biotherapeutics Co., Ltd. do?
BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer immunotherapy drugs in Japan. The company is developing BP2201, a product candidate in Phase I clinical trials to target cancer antigens in various types of cancer; BP2202, Phase I clinical trial to target cancer; and BP2301, a product candidate in Phase I clinical trials for the treatment of solid tumors sarcoma and gynecological cancers.